Transferrin receptor 1 ablation in satellite cells impedes skeletal muscle regeneration through activation of ferroptosis.
Ferroptosis
Fibro/adipogenic progenitors
Satellite cells
Tfr1
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
18
02
2021
received:
26
11
2020
accepted:
16
03
2021
pubmed:
7
5
2021
medline:
26
11
2021
entrez:
6
5
2021
Statut:
ppublish
Résumé
Satellite cells (SCs) are critical to skeletal muscle regeneration. Inactivation of SCs is linked to skeletal muscle loss. Transferrin receptor 1 (Tfr1) is associated with muscular dysfunction as muscle-specific deletion of Tfr1 results in growth retardation, metabolic disorder, and lethality, shedding light on the importance of Tfr1 in muscle physiology. However, its physiological function regarding skeletal muscle ageing and regeneration remains unexplored. RNA sequencing is applied to skeletal muscles of different ages to identify Tfr1 associated to skeletal muscle ageing. Mice with conditional SC ablation of Tfr1 were generated. Between Tfr1 By comparing gene expression between young (2 weeks old, n = 3) and aged (80 weeks old, n = 3) mice among four types of muscles, we identified that Tfr1 expression is declined in muscles of aged mice (~80% reduction, P < 0.005), so as to its protein level in SCs of aged mice. From in vivo and ex vivo experiments, Tfr1 deletion in SCs results in an irreversible depletion of SCs (~60% reduction, P < 0.005) and cell-autonomous defect in SC proliferation and differentiation, leading to skeletal muscle regeneration impairment, followed by labile iron accumulation, lipogenesis, and decreased Gpx4 and Nrf2 protein levels leading to reactive oxygen species scavenger defects. These abnormal phenomena including iron accumulation, activation of unsaturated fatty acid biosynthesis, and lipid peroxidation are orchestrated with the occurrence of ferroptosis in skeletal muscle. Ferroptosis further exacerbates SC proliferation and skeletal muscle regeneration. Ferrostatin-1, a ferroptosis inhibitor, could not rescue ferroptosis. However, intramuscular administration of lentivirus-expressing Tfr1 could partially reduce labile iron accumulation, decrease lipogenesis, and promote skeletal muscle regeneration. Most importantly, declined Tfr1 but increased Slc39a14 protein level on cellular membrane contributes to labile iron accumulation in skeletal muscle of aged rodents (~80 weeks old), leading to activation of ferroptosis in aged skeletal muscle. This is inhibited by ferrostatin-1 to improve running time (P = 0.0257) and distance (P = 0.0248). Satellite cell-specific deletion of Tfr1 impairs skeletal muscle regeneration with activation of ferroptosis. This phenomenon is recapitulated in skeletal muscle of aged rodents and human sarcopenia. Our study provides mechanistic information for developing novel therapeutic strategies against muscular ageing and diseases.
Sections du résumé
BACKGROUND
Satellite cells (SCs) are critical to skeletal muscle regeneration. Inactivation of SCs is linked to skeletal muscle loss. Transferrin receptor 1 (Tfr1) is associated with muscular dysfunction as muscle-specific deletion of Tfr1 results in growth retardation, metabolic disorder, and lethality, shedding light on the importance of Tfr1 in muscle physiology. However, its physiological function regarding skeletal muscle ageing and regeneration remains unexplored.
METHODS
RNA sequencing is applied to skeletal muscles of different ages to identify Tfr1 associated to skeletal muscle ageing. Mice with conditional SC ablation of Tfr1 were generated. Between Tfr1
RESULTS
By comparing gene expression between young (2 weeks old, n = 3) and aged (80 weeks old, n = 3) mice among four types of muscles, we identified that Tfr1 expression is declined in muscles of aged mice (~80% reduction, P < 0.005), so as to its protein level in SCs of aged mice. From in vivo and ex vivo experiments, Tfr1 deletion in SCs results in an irreversible depletion of SCs (~60% reduction, P < 0.005) and cell-autonomous defect in SC proliferation and differentiation, leading to skeletal muscle regeneration impairment, followed by labile iron accumulation, lipogenesis, and decreased Gpx4 and Nrf2 protein levels leading to reactive oxygen species scavenger defects. These abnormal phenomena including iron accumulation, activation of unsaturated fatty acid biosynthesis, and lipid peroxidation are orchestrated with the occurrence of ferroptosis in skeletal muscle. Ferroptosis further exacerbates SC proliferation and skeletal muscle regeneration. Ferrostatin-1, a ferroptosis inhibitor, could not rescue ferroptosis. However, intramuscular administration of lentivirus-expressing Tfr1 could partially reduce labile iron accumulation, decrease lipogenesis, and promote skeletal muscle regeneration. Most importantly, declined Tfr1 but increased Slc39a14 protein level on cellular membrane contributes to labile iron accumulation in skeletal muscle of aged rodents (~80 weeks old), leading to activation of ferroptosis in aged skeletal muscle. This is inhibited by ferrostatin-1 to improve running time (P = 0.0257) and distance (P = 0.0248).
CONCLUSIONS
Satellite cell-specific deletion of Tfr1 impairs skeletal muscle regeneration with activation of ferroptosis. This phenomenon is recapitulated in skeletal muscle of aged rodents and human sarcopenia. Our study provides mechanistic information for developing novel therapeutic strategies against muscular ageing and diseases.
Identifiants
pubmed: 33955709
doi: 10.1002/jcsm.12700
pmc: PMC8200440
doi:
Substances chimiques
Cation Transport Proteins
0
Receptors, Transferrin
0
SLC39A14 protein, mouse
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
746-768Informations de copyright
© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Physiol Rev. 2013 Jan;93(1):23-67
pubmed: 23303905
Cell Res. 2016 Sep;26(9):1021-32
pubmed: 27514700
Trends Endocrinol Metab. 2015 Nov;26(11):608-617
pubmed: 26490383
Cell Metab. 2019 Dec 3;30(6):1040-1054.e7
pubmed: 31523008
Muscle Nerve. 2007 Aug;36(2):223-33
pubmed: 17503500
Genom Data. 2015 Sep 03;6:136-8
pubmed: 26697355
Nat Cell Biol. 2010 Feb;12(2):143-52
pubmed: 20081842
Cell. 2017 Jul 13;170(2):340-351.e12
pubmed: 28709001
Adv Sci (Weinh). 2020 Apr 24;7(12):1903366
pubmed: 32596110
Hum Mol Genet. 2009 Feb 1;18(3):482-96
pubmed: 18996917
Cell. 2015 Oct 22;163(3):643-55
pubmed: 26496606
J Cachexia Sarcopenia Muscle. 2018 Jun;9(3):547-556
pubmed: 29573220
PLoS Genet. 2019 Oct 18;15(10):e1008408
pubmed: 31626629
EMBO J. 2019 May 15;38(10):
pubmed: 30979776
J Cachexia Sarcopenia Muscle. 2021 Jun;12(3):746-768
pubmed: 33955709
Nat Cell Biol. 2010 Feb;12(2):153-63
pubmed: 20081841
J Immunol. 2016 Sep 1;197(5):1914-25
pubmed: 27465531
Life Sci Alliance. 2019 Jun 25;2(3):
pubmed: 31239312
Haematologica. 2020 Aug;105(8):2071-2082
pubmed: 31601687
J Clin Invest. 2018 Jun 1;128(6):2339-2355
pubmed: 29533927
Blood. 2020 Aug 6;136(6):726-739
pubmed: 32374849
Bio Protoc. 2019 Jul 20;9(14):e3313
pubmed: 33654822
PLoS One. 2008 Aug 06;3(8):e2865
pubmed: 18682742
Exp Gerontol. 2013 Nov;48(11):1294-302
pubmed: 23994517
Cell Metab. 2015 Jul 7;22(1):138-50
pubmed: 26028554
Neural Regen Res. 2021 Jul;16(7):1308-1316
pubmed: 33318410
iScience. 2020 Apr 24;23(4):100993
pubmed: 32248062
Haematologica. 2010 Nov;95(11):1801-3
pubmed: 21037324
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
Front Physiol. 2019 Aug 21;10:1074
pubmed: 31496956
J Bone Joint Surg Am. 2002 May;84(5):822-32
pubmed: 12004029
Nature. 1998 Nov 12;396(6707):119-22
pubmed: 9823889
Nat Commun. 2020 Jul 16;11(1):3570
pubmed: 32678081
EBioMedicine. 2015 Oct 04;2(11):1705-17
pubmed: 26870796
Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13612-7
pubmed: 16950869
Cell Metab. 2007 Jun;5(6):426-37
pubmed: 17550778
Cell Death Differ. 2016 Jun;23(6):927-37
pubmed: 26868912
Cell Rep. 2020 Mar 10;30(10):3411-3423.e7
pubmed: 32160546
FASEB J. 2020 May;34(5):6703-6717
pubmed: 32202346
Nat Commun. 2020 Jan 31;11(1):624
pubmed: 32005798
J Cachexia Sarcopenia Muscle. 2019 Jun;10(3):630-642
pubmed: 30895728
Acta Oncol. 2012 Mar;51(3):293-300
pubmed: 22329641
Trends Endocrinol Metab. 2015 Jan;26(1):22-9
pubmed: 25476453
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2672-2680
pubmed: 30692261
Mol Metab. 2017 Nov;6(11):1454-1467
pubmed: 29107292
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970